PPT-Clinical pathway consultations

Sinusitis 12 years and over Sore throat 5 years and over Acute otitis media 1 to 17 years Infected insect bite 1 year and over Impetigo 1 year and over Shingles 18 years and over. E-Agriculture Knowledge exchange and storage product . The Product. The Product. Innovation. Using ICT technology, ECFS was able to build extensive network of the researchers and practitioners with expertise in food security issues in Eurasian region at the open-source C4D platform. Organisations. Workshop New Technologies and Transition: . What Role for CSOs in a Future of E-Democracy. JDE62. Methodology. Introduction . EU online Public Consultations. The EESC and . CSOs. The . Combined Section Meeting 2015. February 4. th. -7. th. , 2015 – Indianapolis, IN. PHALAN BOLDEN RN, MSN FNP-CMC MAIN. LATASHA RUFFIN PT, DPT CMC-MAIN. DISCLAIMER. There is no relationship that can reasonably be viewed as creating a conflict of interest, or the appearance of a conflict of interest that might bias the content of the presentation. Nor is there any significant financial interest in any product instrument, device, service or material discussed in the presentation including the source of any third party compensation related to the presentation. . Objectives. Demonstrate . an understanding of the NSTEMI clinical pathway.. Understand the importance of . early and consistent . education throughout hospital stay.. Demonstrate . the knowledge of . Stirling Bryan, PhD. Graham Scotland, PhD. Mohsen Sadatsafavi, . PhD. Overview of session. Stirling Bryan:. In Search of Efficiency, Consistency, Fairness, and Impact in . HTA. Graham Scotland. Modelling screening and treatment pathways for diabetic retinopathy. Combined Section Meeting 2015. February 4. th. -7. th. , 2015 – Indianapolis, IN. PHALAN BOLDEN RN, MSN FNP-CMC MAIN. LATASHA RUFFIN PT, DPT CMC-MAIN. DISCLAIMER. There is no relationship that can reasonably be viewed as creating a conflict of interest, or the appearance of a conflict of interest that might bias the content of the presentation. Nor is there any significant financial interest in any product instrument, device, service or material discussed in the presentation including the source of any third party compensation related to the presentation. . Page 1of 13PENICILLIN ALLERGY DELABELING ALGORITHMHistory PhysicalPCN allergy identifiedOnly do test dose during day shift and if a Parent/guardian is present if not you can Inclusion CriteriaAdmitte Page 1 of 19 !If after hours/weekend, refer to NICU(call CHCO OneCall to request NICU consultation) Infant at birth Provider to complete:Airway assessmentFeeding and growth assessment Call Cleft RN Page 1 of 12 CONCUSSION Age 6 to 18 yearsALGORITHM Triage AssessmentTargeted history and examVital signsNeuro check with pupil examRequest immediate clinician evaluation if clinical concern or signi Page 1 of 13 VIRAL CROUPALGORITHM: Outpatient/ED Management Inclusion Criteria Previously healthy Age 6 months to 6 years Exclusion Criteria Symptoms suggestive of an alternative diagnosis Known up Page 1 of 13 PROTEIN ENERGY MALNUTRITION (FAILURE TO THRIVE)ALGORITHM Inclusion criteria Conduct Initial AssessmentHistory and physical (Weight height, : edema Consider basic labs based on H&(recomm Page 1 of 20 RISK SPINAL FUSAlgorithm 1: Preoperative Inclusion Criteria Patients having spine surgery without other complex chronic conditions Exclusion Criteria High - risk spinal fusion patien Nanosimilars. Beat . Flühmann. Global Lead NBCD . Vifor. . Pharma. Ltd. Steering. committe . member. . of. . the. NBCD Working Group. NBCD:. A. n increasingly important drug class. 2. Nanosimilars. Sandie Keall. Agenda. Overview of Common Conditions Service. Checklist and requirements to deliver. Summarise the training on . cliniskills. Each condition in brief linked to the clinical pathways. History taking – importance for the assessment process.